Patent ID: 7820787

Claim:
A method of treating a subject with cancer by administration of a macrocyclic metal chelate, said method comprising the steps of: (a) administering to said subject an antibody comprising an antigen recognition domain that recognizes said macrocyclic metal chelate, wherein said antibody comprises: i) a light chain comprising: a) a first CDR having the sequence of SEQ ID NO:2; b) a second CDR having a sequence selected from the group consisting of: i) SEQ ID NO:3; and ii) SEQ ID NO:3 containing a cysteine substitution wherein position 2 is substituted by a cysteine; c) a third CDR having the sequence of SEQ ID NO:4; ii) a heavy chain comprising: a) a first CDR having the sequence of SEQ ID NO:6; b) a second CDR having a sequence selected from the group consisting of: i) SEQ ID NO:7; ii) SEQ ID NO: 7 containing a cysteine substitution wherein position 5 has been substituted by a cysteine; iii) SEQ ID NO:7 containing a cysteine substitution wherein position 6 has been substituted by a cysteine; and iv) SEQ ID NO:7 containing a cysteine substitution wherein position 7 has been substituted by a cysteine; c) a third CDR having the sequence of SEQ ID NO:8; wherein said antibody comprises at least one of said cysteine substitutions, and wherein said antibody binds substituted or unsubstituted 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA); and a targeting moiety that binds specifically to a cancer cell by binding with a member selected from a cell surface receptor and cell surface antigen, thereby forming a cell-antibody complex; and (b) administering to said subject said macrocyclic metal chelate, wherein the macrocyclic metal chelate is a substituted or unsubstituted 1,4,7,10-tetraazacyclododecane-N,N′,N″N′″-tetraacetic acid (DOTA) complexed to a metal ion.